# Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

> **NCT02809092** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hospital de Clinicas de Porto Alegre** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** NK Cells + Chemotherapy Starting

## Key facts

- **NCT ID:** NCT02809092
- **Lead sponsor:** Hospital de Clinicas de Porto Alegre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-01
- **Primary completion:** 2019-09-30
- **Final completion:** 2020-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02809092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02809092, "Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02809092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*